Financing Through Third-Party Allotments, Convertible Bonds and Stock Acquisition Rights
First written in FY2017-Q3. 32 of 34 entries say "Advanced", first in FY2017. Latest entry: 2026-10-01.
4 other companies' latest entry also says "Advanced".
- FY2025AdvancedAnnual report
「At a meeting of its board of directors held on 3 December 2025, the company resolved to issue the 20th stock acquisition rights subject to adjustment of the exercise price through a third-party allotment to Macquarie Bank Limited.」
The company resolved to issue 590,000 units of the 20th stock acquisition rights, representing 59,000,000 potential shares, and allocate the assumed proceeds of ¥1,862 million, based on full exercise, to development costs for regenerative medicine products for chronic limb-threatening ischemia, promotional expenses for the cell-processing business, and headquarters working capital. - FY2025-H1AchievedAnnual report
「All 525,000 units of the 19th stock acquisition rights, representing 52,500,000 shares, had been exercised, raising ¥2,605 million.」
All of the 19th stock acquisition rights had been exercised, resulting in the issuance of 52,500,000 shares and the completion of ¥2,605 million in financing. - FY2024-Q2AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the relevant quarterly accounting period (units): 25,000 Number of shares delivered upon exercise during the relevant quarterly accounting period (shares): 2,500,000 Financing proceeds from exercises during the relevant quarterly accounting period (thousand yen): 114,000」
For the 19th stock acquisition rights, 25,000 units were exercised during the second-quarter accounting period, resulting in the delivery of 2,500,000 shares and ¥114 million in financing proceeds. Cumulative financing proceeds reached ¥2,238.994 million. - FY2024-Q1AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the relevant quarterly accounting period (units): 213,500 Number of shares delivered upon exercise during the relevant quarterly accounting period (shares): 21,350,000 Financing proceeds from exercises during the relevant quarterly accounting period (thousand yen): 990,082」
For the 19th stock acquisition rights, 213,500 units were exercised during the first quarter, resulting in the delivery of 21,350,000 shares and ¥990.082 million in financing proceeds. On a cumulative basis, the figures were 41,675,000 shares and ¥2,124.994 million. - FY2023AdvancedAnnual report
「The company is raising funds through the exercise of the 19th stock acquisition rights.」
For the 19th stock acquisition rights, the company issued 20,325,000 shares and raised ¥1,134.911 million during the fiscal year. - FY2023-Q3AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the relevant quarterly accounting period (units): 65,210」
For the 19th stock acquisition rights, 65,210 units were exercised during the quarter, resulting in the delivery of 6,521,000 shares and ¥418.32 million in financing proceeds. On a cumulative basis, the figures were 81,510 units, 8,151,000 shares and ¥521.352 million. - FY2023-Q2AdvancedAnnual report
「The 19th stock acquisition rights issued by the company on 6 March 2023 were exercised. As a result, capital stock and capital surplus each increased by ¥52.029 million.」
Following the issuance of the 19th stock acquisition rights, 16,300 units were exercised during the second-quarter accounting period, resulting in the delivery of 1,630,000 shares and ¥103.032 million in financing proceeds. - FY2022-Q3AdvancedAnnual report
「The 18th stock acquisition rights issued by the company on 1 September 2021 were exercised, and all rights had been exercised in full.」
All of the 18th stock acquisition rights were exercised during the cumulative period of the third quarter, resulting in the delivery of a cumulative 34,000,000 shares and ¥1,668.465 million in financing proceeds. - FY2022-Q2AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the relevant quarterly accounting period (units): 120,500」
For the 18th stock acquisition rights, 120,500 units were exercised during the second-quarter accounting period, resulting in the delivery of 12,050,000 shares and ¥546.847 million in financing proceeds. On a cumulative basis, the figures were 192,700 units, 19,270,000 shares and ¥962.653 million. - FY2022-Q1AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the relevant quarterly accounting period (units): 62,000」
For the 18th stock acquisition rights, 62,000 units were exercised during the first quarter, resulting in the delivery of 6,200,000 shares and ¥345.467 million in financing proceeds. On a cumulative basis, the figures were 72,200 units, 7,220,000 shares and ¥415.805 million. - FY2021-Q3AdvancedAnnual report
「At a meeting of its board of directors held on 16 August 2021, the company resolved to issue the 18th stock acquisition rights subject to adjustment of the exercise price through a third-party allotment to Macquarie Bank Limited.」
The company resolved to issue 340,000 units of the 18th stock acquisition rights and allocate the assumed proceeds of ¥2,703 million, based on full exercise, to capital investment and organisational development for expanding the CDMO business and other operations, headquarters working capital, and costs related to capital and business alliances. - FY2021-Q2AdvancedAnnual report
「The main source of cash was ¥828 million in proceeds from share issuance.」
The exercise of the 17th stock acquisition rights and other instruments raised ¥828 million through share issuance during the cumulative period of the second quarter. - FY2021-Q1AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the first-quarter accounting period (units): 92,550」
For the 17th stock acquisition rights, 92,550 units were exercised during the first quarter, resulting in the delivery of 9,255,000 shares and ¥577.128 million in financing proceeds. On a cumulative basis, the figures were 113,550 units, 11,355,000 shares and ¥761.123 million. - FY2020-Q3AdvancedAnnual report
「At a meeting of its board of directors held on 19 June 2020, the company resolved to issue the 16th stock acquisition rights subject to adjustment of the exercise price through a third-party allotment to Macquarie Bank Limited, and payment of the total issue price of ¥24.436 million was completed on 6 July 2020.」
As exercise of the 14th and 15th stock acquisition rights progressed, the company issued the 16th stock acquisition rights and set a financing target of ¥1,890.428 million. Subsequently, on 4 August 2020 after the filing, all rights had been exercised. - FY2020-Q2AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the relevant quarterly accounting period (units): 36,950, number of shares delivered upon exercise during the relevant quarterly accounting period (shares): 3,695,000, financing proceeds from exercises during the relevant quarterly accounting period (thousand yen): 186,424」
For the 14th stock acquisition rights, 36,950 units were exercised during the second-quarter accounting period, resulting in the issuance of 3,695,000 shares and ¥186.424 million in financing proceeds. Cumulative financing proceeds reached ¥594.766 million. - FY2020-Q1AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the relevant quarterly accounting period (units): 46,450 Number of shares delivered upon exercise during the relevant quarterly accounting period (shares): 4,645,000 Financing proceeds from exercises during the relevant quarterly accounting period (thousand yen): 266,547」
For the 14th stock acquisition rights, 46,450 units were exercised in the first quarter, resulting in the issuance of 4,645,000 shares and ¥266.547 million in financing proceeds. - FY2019AdvancedAnnual report
「During the fiscal year, 25,450 units of the 14th stock acquisition rights were exercised, resulting in the issuance of 2,545,000 shares and ¥141.795 million in proceeds.」
Exercise of the 14th stock acquisition rights progressed, resulting in the issuance of 2,545,000 shares and ¥141.795 million in financing proceeds. The 15th stock acquisition rights remained outstanding as of the end of the period. - FY2019-Q3AdvancedAnnual report
「At present, the company is maintaining a stable cash position by securing funds through the steady execution of structural reforms, as well as by raising funds for the development costs of regenerative medicine products through the issuance of the 14th and 15th stock acquisition rights in June this year」
The company issued the 14th and 15th stock acquisition rights in June 2019 as a new means of raising funds for the development costs of regenerative medicine products. The target number of shares was 17,000,000 for the 14th and 7,000,000 for the 15th, with a minimum exercise price of ¥40 for each. - FY2019-Q1AdvancedAnnual report
「Number of adjustment-clause bonds with stock acquisition rights and other instruments exercised during the first-quarter accounting period (units): 1,000 Number of shares delivered upon exercise during the first-quarter accounting period (shares): 100,000 Financing proceeds from exercises during the first-quarter accounting period (thousand yen): 9,500」
For the 13th stock acquisition rights, 1,000 units were exercised, resulting in the delivery of 100,000 shares and ¥9.5 million in financing proceeds. On a cumulative basis, the figures were 1,765,000 shares and ¥183.885 million. - FY2018-Q3AdvancedAnnual report
「The 12th stock acquisition rights issued by the company on 19 June 2017, the 4th unsecured convertible bond-type bonds with stock acquisition rights issued on 13 February 2018, and the 13th stock acquisition rights were exercised.」
Under the 4th convertible bond-type bonds with stock acquisition rights, a cumulative 7,597,100 shares were delivered, while 1,665,000 shares were delivered under the 13th stock acquisition rights, and ¥174.385 million in financing proceeds was also recorded. - FY2018-Q2AdvancedAnnual report
「During the cumulative period of the second quarter, capital stock and capital surplus each increased by ¥450.406 million」
The exercise of rights under the 4th convertible bond-type bonds with stock acquisition rights and other instruments resulted in the delivery of 6,952,100 shares, while capital stock and capital surplus each increased by ¥450.406 million. - FY2018-Q1AdvancedAnnual report
「At a meeting of its board of directors held on 26 January 2018, the company resolved to issue, through a third-party allotment, the 4th unsecured convertible bond-type bonds with stock acquisition rights subject to adjustment of the conversion price and the 13th stock acquisition rights subject to adjustment of the exercise price.」
The company resolved to issue ¥900 million of the 4th unsecured convertible bond-type bonds with stock acquisition rights and the 13th stock acquisition rights, and payment was completed on 13 February 2018. - FY2017AdvancedAnnual report
「During the consolidated fiscal year, the company raised funds through the issuance of new shares, the 3rd unsecured convertible bond-type bonds with stock acquisition rights subject to adjustment of the conversion price, and the 12th stock acquisition rights subject to adjustment of the exercise price.」
The company raised funds, including ¥1,619.773 million in proceeds from share issuance, through a third-party allotment, conversion of bonds with stock acquisition rights, and exercise of stock acquisition rights. - FY2017-Q3First statedAnnual report
「On 19 June 2017, we issued new shares through a private placement to Macquarie Bank Limited and CMIC Holdings Co., Ltd.」
The Company issued 1,372,400 shares through a private placement and issued the Third Unsecured Convertible Bonds with Stock Acquisition Rights and the Twelfth Stock Acquisition Rights.